Patents by Inventor Bethany Lyn Kormos
Bethany Lyn Kormos has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230167080Abstract: Described herein are compounds of Formula I, wherein the variables are defined herein, their use as branched-chain alpha keto acid dehydrogenase kinase inhibitors and/or degraders, pharmaceutical compositions containing such compounds and their use to treat, for example, diabetes, kidney disease, NASH and heart failure.Type: ApplicationFiled: November 30, 2022Publication date: June 1, 2023Applicant: Pfizer Inc.Inventors: Leanne Marie BUZON, Kimberly O'Keefe CAMERON, Kevin Francis DEBOYACE, Kevin James FILIPSKI, David Andrew GRIFFITH, Bethany Lyn KORMOS, Shenping LIU, Luis Angel MARTINEZ ALSINA, Matthew Richard REESE, Rachel Jane ROTH FLACH, Yuan ZHANG
-
Patent number: 11542270Abstract: Described herein are compounds of Formula I, wherein R1, R2, and R3 are defined herein, their use as branched-chain alpha keto acid dehydrogenase kinase inhibitors, pharmaceutical compositions containing such inhibitors and the use of such inhibitors to treat, for example, diabetes, NASH and heart failure.Type: GrantFiled: June 26, 2020Date of Patent: January 3, 2023Assignee: Pfizer Inc.Inventors: Samit Kumar Bhattacharya, Leanne Marie Buzon, Kevin James Filipski, David Andrew Griffith, Bethany Lyn Kormos, Luis Angel Martinez-Alsina, Russell Alan Miller, Matthew Richard Reese, Rachel Jane Roth Flach, Yuan Zhang
-
Publication number: 20220363673Abstract: Described herein are compounds of Formula I, wherein R1, R2, and R3 are defined herein, their use as branched-chain alpha keto acid dehydrogenase kinase inhibitors, pharmaceutical compositions containing such inhibitors and the use of such inhibitors to treat, for example, diabetes, NASH and heart failure.Type: ApplicationFiled: June 24, 2020Publication date: November 17, 2022Applicant: Pfizer Inc.Inventors: Samit Kumar Bhattacharya, Christopher Ryan Butler, Kevin James Filipski, Bethany Lyn Kormos, Luis Angel Martinez-Alsina, Russell Alan Miller, Kiyoyuki Omoto, Brian Raymer, Matthew Richard Reese, Rachel Jane Roth Flach, Yuan Zhang
-
Patent number: 11390623Abstract: The present invention provides compounds of Formula (I): and pharmaceutically acceptable salts thereof wherein the variables R1, R2, R3, R4, R5, a and A are as defined herein; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses for treating D3-mediated (or D3-associated) disorders including, e.g., substance addiction, substance abuse, schizophrenia (e.g., its cognitive symptoms), cognitive impairment (e.g., cognitive impairment associated with schizophrenia, AD or PD), Parkinson's disease, mania, anxiety, impulse control disorders, sexual disorders and depression.Type: GrantFiled: January 23, 2020Date of Patent: July 19, 2022Assignee: PFIZER INC.Inventors: Thomas Allen Chappie, Jaclyn Louise Henderson, Joseph Michael Young, Travis T. Wager, Bethany Lyn Kormos, Nandini Chaturbhai Patel, Simone Sciabola, Jamison Bryce Tuttle, Patrick Robert Verhoest, Joseph Walter Tucker
-
Patent number: 11312713Abstract: The present invention provides novel imidazo[4,5-c]quinoline derivatives of Formula (I), and the pharmaceutically acceptable salts thereof I wherein R1, R2 and R3 are as defined in the specification. The invention is also directed to pharmaceutical compositions comprising the compounds of Formula I and to use of the compounds in the treatment of diseases associated with LRRK2, such as neurodegenerative diseases including Parkinson's disease or Alzheimer's disease, cancer, Crohn's disease or leprosy.Type: GrantFiled: March 6, 2018Date of Patent: April 26, 2022Assignee: Pfizer Inc.Inventors: Michael Aaron Brodney, Thomas Allen Chappie, Jinshan Michael Chen, Jotham Wadsworth Coe, Karen Jean Coffman, Paul Galatsis, Michelle Renee Garnsey, Christopher John Helal, Jaclyn Louise Henderson, Bethany Lyn Kormos, Ravi G. Kurumbail, Luis Angel Martinez-Alsina, Martin Youngjin Pettersson, Matthew Richard Reese, Colin Richard Rose, Antonia Friederike Stepan, Patrick Robert Verhoest, Travis T. Wager, Joseph Scott Warmus, Yuan Zhang
-
Publication number: 20210355117Abstract: The present invention provides novel imidazo[4,5-c]quinoline derivatives of Formula (I), and the pharmaceutically acceptable salts thereof I wherein R1, R2 and R3 are as defined in the specification. The invention is also directed to pharmaceutical compositions comprising the compounds of Formula I and to use of the compounds in the treatment of diseases associated with LRRK2, such as neurodegenerative diseases including Parkinson's disease or Alzheimer's disease, cancer, Crohn's disease or leprosy.Type: ApplicationFiled: March 6, 2018Publication date: November 18, 2021Inventors: Michael Aaron BRODNEY, Thomas Allen CHAPPIE, Jinshan Michael CHEN, Jotham Wadsworth COE, Karen Jean COFFMAN, Paul GALATSIS, Michelle Renee GARNSEY, Christopher John HELAL, Jaclyn Louise Henderson, Bethany Lyn KORMOS, Ravi G. KURUMBAIL, Luis Angel MARTINEZ-ALSINA, Martin Youngjin PETTERSSON, Matthew Richard REESE, Colin Richard ROSE, Antonia Friederike STEPAN, Patrick Robert VERHOEST, Travis T. WAGER, Joseph Scott WARMUS, Yuan ZHANG
-
Patent number: 11161844Abstract: The present invention provides novel cyclic substituted imidazo[4,5-c]quinoline derivatives of Formula (I), and the pharmaceutically acceptable salts thereof; wherein R1, R2, R4, R5, R6, X and Z are as defined in the specification. The invention is also directed to pharmaceutical compositions comprising the compounds of Formula I and to use of the compounds in the treatment of diseases associated with LRRK2, such as neurodegenerative diseases including Parkinson's disease or Alzheimer's disease, cancer, Crohn's disease or leprosy.Type: GrantFiled: March 1, 2018Date of Patent: November 2, 2021Assignee: PFIZER INC.Inventors: Thomas Allen Chappie, Paul Galatsis, Michelle Renee Garnsey, Christopher John Helal, Jaclyn Louise Henderson, Bethany Lyn Kormos, Ravi G. Kurumbail, Luis Angel Martinez-Alsina, Martin Youngjin Pettersson, Antonia Friederike Stepan, Travis T. Wager
-
Patent number: 11059833Abstract: Described herein are compounds of Formula I, wherein R1, R2, and R3 are defined herein, their use as branched-chain alpha keto acid dehydrogenase kinase inhibitors, pharmaceutical compositions containing such inhibitors and the use of such inhibitors to treat, for example, diabetes, NASH and heart failure.Type: GrantFiled: October 23, 2020Date of Patent: July 13, 2021Assignee: Pfizer Inc.Inventors: Samit Kumar Bhattacharya, Leanne Marie Buzon, Kevin James Filipski, David Andrew Griffith, Bethany Lyn Kormos, Luis Angel Martinez-Alsina, Russell Alan Miller, Matthew Richard Reese, Rachel Jane Roth Flach, Yuan Zhang
-
Publication number: 20210087204Abstract: Described herein are compounds of Formula I, wherein R1, R2, and R3 are defined herein, their use as branched-chain alpha keto acid dehydrogenase kinase inhibitors, pharmaceutical compositions containing such inhibitors and the use of such inhibitors to treat, for example, diabetes, NASH and heart failure.Type: ApplicationFiled: October 23, 2020Publication date: March 25, 2021Applicant: Pfizer Inc.Inventors: Samit Kumar Bhattacharya, Leanne Marie Buzon, Kevin James Filipski, David Andrew Griffith, Bethany Lyn Kormos, Luis Angel Martinez-Alsina, Russell Alan Miller, Matthew Richard Reese, Rachel Jane Roth Flach, Yuan Zhang
-
Publication number: 20210024536Abstract: Described herein are compounds of Formula I, wherein R1, R2, and R3 are defined herein, their use as branched-chain alpha keto acid dehydrogenase kinase inhibitors, pharmaceutical compositions containing such inhibitors and the use of such inhibitors to treat, for example, diabetes, NASH and heart failure.Type: ApplicationFiled: June 26, 2020Publication date: January 28, 2021Applicant: Pfizer Inc.Inventors: Samit Kumar Bhattacharya, Leanne Marie Buzon, Kevin James Filipski, David Andrew Griffith, Bethany Lyn Kormos, Luis Angel Martinez-Alsina, Russell Alan Miller, Matthew Richard Reese, Rachel Jane Roth Flach, Yuan Zhang
-
Publication number: 20200157098Abstract: The present invention provides compounds of Formula (I): and pharmaceutically acceptable salts thereof wherein the variables R1, R2, R3, R4, R5, a and A are as defined herein; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses for treating D3-mediated (or D3-associated) disorders including, e.g., substance addiction, substance abuse, schizophrenia (e.g., its cognitive symptoms), cognitive impairment (e.g., cognitive impairment associated with schizophrenia, AD or PD), Parkinson's disease, mania, anxiety, impulse control disorders, sexual disorders and depression.Type: ApplicationFiled: January 23, 2020Publication date: May 21, 2020Inventors: Thomas Allen Chappie, Jaclyn Louise Henderson, Joseph Michael Young, Travis T. Wager, Bethany Lyn Kormos, Nandini Chaturbhai Patel, Simone Sciabola, Jamison Bryce Tuttle, Patrick Robert Verhoest, Joseph Walter Tucker
-
Patent number: 10590128Abstract: The present invention provides compounds of Formula (I): and pharmaceutically acceptable salts thereof wherein the variables R1, R2, R3, R4, R5, a and A are as defined herein; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses for treating D3-mediated (or D3-associated) disorders including, e.g., substance addiction, substance abuse, schizophrenia (e.g., its cognitive symptoms), cognitive impairment (e.g., cognitive impairment associated with schizophrenia, AD or PD), Parkinson's disease, mania, anxiety, impulse control disorders, sexual disorders and depression.Type: GrantFiled: January 9, 2017Date of Patent: March 17, 2020Assignee: Pfizer, Inc.Inventors: Thomas Allen Chappie, Jaclyn Louise Henderson, Joseph Michael Young, Travis T. Wager, Bethany Lyn Kormos, Nandini Chaturbhai Patel, Simone Sciabola, Jamison Bryce Tuttle, Patrick Robert Verhoest, Joseph Walter Tucker
-
Publication number: 20200039977Abstract: The present invention provides novel cyclic substituted imidazo[4,5-c]quinoline derivatives of Formula (I), and the pharmaceutically acceptable salts thereof, wherein R1, R2, R4, R5, R6, X and Z are as defined in the specification. The invention is also directed to pharmaceutical compositions comprising the compounds of Formula I and to use of the compounds in the treatment of diseases associated with LRRK2, such as neurodegenerative diseases including Parkinson's disease or Alzheimer's disease, cancer, Crohn's disease or leprosy.Type: ApplicationFiled: March 1, 2018Publication date: February 6, 2020Inventors: Thomas Allen Chappie, Paul Galatsis, Michelle Renee Garnsey, Christopher John Helal, Jaclyn Louise Henderson, Bethany Lyn Kormos, Ravi G. Kurumbail, Luis Angel Martinez-Alsina, Martin Youngjin Pettersson, Antonia Friederike Stepan, Travis T. Wager
-
Publication number: 20190047997Abstract: The present invention provides compounds of Formula (I): and pharmaceutically acceptable salts thereof wherein the variables R1, R2, R3, R4, R5, a and A are as defined herein; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses for treating D3-mediated (or D3-associated) disorders including, e.g., substance addiction, substance abuse, schizophrenia (e.g., its cognitive symptoms), cognitive impairment (e.g., cognitive impairment associated with schizophrenia, AD or PD), Parkinson's disease, mania, anxiety, impulse control disorders, sexual disorders and depression.Type: ApplicationFiled: January 9, 2017Publication date: February 14, 2019Applicant: Pfizer Inc.Inventors: Thomas Allen Chappie, Jaclyn Louise Henderson, Joseph Michael Young, Travis T. Wager, Bethany Lyn Kormos, Nandini Chaturbhai Patel, Simone Sciabola, Jamison Bryce Tuttle, Patrick Robert Verhoest, Joseph Walter Tucker
-
Patent number: 10039753Abstract: The present invention provides novel imidazo[4,5-c]quinoline and imidazo[4,5-c][1,5]naphthyridine derivatives of Formula (I), and the pharmaceutically acceptable salts thereof wherein R1, R1a, R1b, R2, R4, R5, R6, X and Z are as defined in the specification. The invention is also directed to pharmaceutical compositions comprising the compounds of Formula (I) and to use of the compounds in the treatment of diseases associated with LRRK2, such as neurodegenerative diseases including Parkinson's disease or Alzheimer's disease, cancer, Crohn's disease or leprosy.Type: GrantFiled: September 12, 2016Date of Patent: August 7, 2018Assignee: Pfizer Inc.Inventors: Karen Jean Coffman, Paul Galatsis, Michelle Renee Garnsey, Jaclyn Louise Henderson, Bethany Lyn Kormos, Ravi G. Kurumbail, Martin Youngjin Pettersson, Matthew Richard Reese, Antonia Friederike Stepan, Patrick Robert Verhoest, Travis T. Wager
-
Patent number: 9695171Abstract: The present invention provides novel 3,4-disubstituted-1H-pyrrolo[2,3-b]pyridine derivatives and 4,5-disubstituted-7H-pyrrolo[2,3-c]pyridazine derivatives of Formula I, and the pharmaceutically acceptable salts thereof wherein R1, R2, R3, R4 and X are as defined in the specification. The invention is also directed to pharmaceutical compositions comprising the compounds of formula I and to use of the compounds in the treatment of diseases associated with LRRK2, such as neurodegenerative diseases including Parkinson's disease or Alzheimer's disease, cancer, Crohn's disease or leprosy.Type: GrantFiled: December 3, 2014Date of Patent: July 4, 2017Assignee: Pfizer Inc.Inventors: Paul Galatsis, Matthew Merrill Hayward, Bethany Lyn Kormos, Travis T. Wager, Lei Zhang, Jaclyn Louise Henderson, Ravi G. Kurumbail, Patrick Robert Verhoest, Antonia Friederike Stepan
-
Patent number: 9642855Abstract: The present invention provides novel 4,5-disubstituted-7H-pyrrolo[2,3-d]pyrimidine derivatives of Formula I, and the pharmaceutically acceptable salts thereof wherein R1, R2, R3, R4 and R5 are as defined in the specification. The invention is also directed to pharmaceutical compositions comprising the compounds of formula I and to use of the compounds in the treatment of diseases associated with LRRK2, such as neurodegenerative diseases including Parkinson's disease or Alzheimer's disease, cancer, Crohn's disease or leprosy.Type: GrantFiled: August 31, 2015Date of Patent: May 9, 2017Assignee: Pfizer Inc.Inventors: Paul Galatsis, Matthew Merrill Hayward, Bethany Lyn Kormos, Travis T. Wager, Lei Zhang, Antonia Friederike Stepan, Jaclyn Louise Henderson, Ravi G. Kurumbail, Patrick Robert Verhoest
-
Publication number: 20170073343Abstract: The present invention provides novel imidazo[4,5-c]quinoline and imidazo[4,5-c][1,5]naphthyridine derivatives of Formula (I), and the pharmaceutically acceptable salts thereof wherein R1, R1a, R1b, R2, R4, R5, R6, X and Z are as defined in the specification. The invention is also directed to pharmaceutical compositions comprising the compounds of Formula (I) and to use of the compounds in the treatment of diseases associated with LRRK2, such as neurodegenerative diseases including Parkinson's disease or Alzheimer's disease, cancer, Crohn's disease or leprosy.Type: ApplicationFiled: September 12, 2016Publication date: March 16, 2017Applicant: Pfizer Inc.Inventors: Paul Galatsis, Jaclyn Louise Henderson, Bethany Lyn Kormos, Ravi G. Kurumbail, Matthew Richard Reese, Antonia Friederike Stepan, Patrick Robert Verhoest, Travis T. Wager, Martin Youngjin Pettersson, Michelle Renee Garnsey
-
Publication number: 20170002000Abstract: The present invention provides novel 3,4-disubstituted-1H-pyrrolo[2,3-b]pyridine derivatives and 4,5-disubstituted-7H-pyrrolo[2,3-c]pyridazine derivatives of Formula I, and the pharmaceutically acceptable salts thereof wherein R1, R2, R3, R4 and X are as defined in the specification. The invention is also directed to pharmaceutical compositions comprising the compounds of formula I and to use of the compounds in the treatment of diseases associated with LRRK2, such as neurodegenerative diseases including Parkinson's disease or Alzheimer's disease, cancer, Crohn's disease or leprosy.Type: ApplicationFiled: December 3, 2014Publication date: January 5, 2017Applicant: Pfizer Inc.Inventors: Paul Galatsis, Matthew Merrill Hayward, Bethany Lyn Kormos, Travis T. Wager, Lei Zhang, Jaclyn Louise Henderson, Ravi G. Kurumbail, Patrick Robert Verhoest, Antonia Friederike Stepan
-
Patent number: 9296761Abstract: The present invention is directed to a new class of triazine derivatives as described by formula I below in which A, X, R1, R2, R3, and R4 are as defined herein and to the use of the compounds as PDE10 inhibitors.Type: GrantFiled: August 19, 2015Date of Patent: March 29, 2016Assignee: Pfizer Inc.Inventors: Thomas Allen Chappie, Christopher John Helal, Bethany Lyn Kormos, Jamison Bryce Tuttle, Patrick Robert Verhoest